Targeting telomerase in hematologic malignancy

Future Oncology

Volumn 6, Issue 5, 2010, Pages 769-789

  Maritz, Michelle F ^a   Napier, Christine E ^b   Wen, Victoria W ^a   MacKenzie, Karen L ^a  

^a University of New South Wales   (Australia)

^b CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Bone marrow failure; Hematopoiesis; Leukemia; Replicative lifespan; Telomerase; Telomere; Therapeutic

Indexed keywords

ADENINE; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BIBR 1532; CD34 ANTIGEN; CD38 ANTIGEN; CD45RA ANTIGEN; CD71 ANTIGEN; CYTARABINE; DAUNORUBICIN; DENDRITIC CELL VACCINE; DNA; FJ 5002; GUANINE; GUANINE QUADRUPLEX; IMATINIB; IMETELSTAT; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR; SMALL INTERFERING RNA; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESTATIN; THYMINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; BONE MARROW DEPRESSION; CANCER CELL CULTURE; CANCER RESEARCH; CARCINOGENESIS; CELL DIVISION; CELL PROLIFERATION; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DNA REPAIR; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; METASTASIS INHIBITION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEOTIDE REPEAT; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; REVIEW; RNA INTERFERENCE; T CELL LEUKEMIA; T CELL LYMPHOMA; TELOMERE; THROMBOCYTOPENIA;

ANIMALS; HEMATOLOGIC NEOPLASMS; HUMANS; TELOMERASE; TELOMERE;

EID: 77952527445     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.42     Document Type: Review

References (238)

1. Bodnar AG, Ouellette M, Frolkis M et al.: Extension of life-span by introduction of telomerase into normal human cells. Science 279 (5349), 349-352 (1998).
2. Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345 (6274), 458-460 (1990).
3. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC: Telomere reduction in human colorectal carcinoma and with ageing. Nature 346 (6287), 866-868 (1990).
4. n, present at the telomeres of human chromosomes. Proc. Natl Acad. Sci. USA 85 (18), 6622-6626 (1988).
5. McEachern MJ, Iyer S, Fulton TB, Blackburn EH: Telomere fusions caused by mutating the terminal region of telomeric DNA. Proc. Natl Acad. Sci. USA 97 (21), 11409-11414 (2000).
6. Makarov VL, Hirose Y, Langmore JP: Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 88 (5), 657-666 (1997).
7. de Lange T: Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19 (18), 2100-2110 (2005).
8. de Lange T: T-loops and the origin of telomeres. Nat. Rev. Mol. Cell. Biol. 5 (4), 323-329 (2004).
9. Greider CW: Telomeres do D-loop-T-loop. Cell 97 (4), 419-422 (1999).
10. Griffth JD, Comeau L, Rosenfeld S et al.: Mammalian telomeres end in a large duplex loop. Cell 97 (4), 503-514 (1999).
11. Hug N, Lingner J: Telomere length homeostasis. Chromosoma 115 (6), 413-425 (2006).
12. Zeichner SL, Palumbo P, Feng Y et al.: Rapid telomere shortening in children. Blood 93 (9), 2824-2830 (1999).
13. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM: Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc. Natl Acad. Sci. USA 91 (21), 9857-9860 (1994).
14. Watson JD: Origin of concatemeric T7 DNA. Nat. New Biol. 239 (94), 197-201 (1972).
15. +-mediated fenton reactions has possible biological implications. J. Biol. Chem. 274 (2), 962-971 (1999).
16. von Zglinicki T, Pilger R, Sitte N: Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic. Biol. Med. 28 (1), 64-74 (2000).
17. Oikawa S, Kawanishi S: Site-specifc DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening. FEBS Lett. 453 (3), 365-368 (1999).
18. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L et al.: A DNA damage checkpoint response in telomere-initiated senescence. Nature 426 (6963), 194-198 (2003).
19. Ben-Porath I, Weinberg RA: The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol. 37 (5), 961-976 (2005).
20. Murnane JP, Sabatier L: Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. Bioessays 26 (11), 1164-1174 (2004).
21. Chin K, de Solorzano CO, Knowles D et al.: In situ analyses of genome instability in breast cancer. Nat. Genet. 36 (9), 984-988 (2004).
22. Rudolph KL, Millard M, Bosenberg MW, DePinho RA: Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 28 (2), 155-159 (2001).
23. Gisselsson D, Jonson T, Petersen A et al.: Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc. Natl Acad. Sci. USA 98 (22), 12683-12688 (2001).
24. Gisselsson D, Pettersson L, Hoglund M et al.: Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc. Natl Acad. Sci. USA 97 (10), 5357-5362 (2000).
25. Kim NW, Piatyszek MA, Prowse KR et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 266 (5193), 2011-2015 (1994).
26. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW: Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18 (2), 173-179 (1996).
27. Morin GB: The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59 (3), 521-529 (1989).
28. Blackburn EH, Greider CW, Henderson E, Lee MS, Shampay J, Shippen-Lentz D: Recognition and elongation of telomeres by telomerase. Genome 31 (2), 553-560 (1989).
29. Shippen-Lentz D, Blackburn EH: Telomere terminal transferase activity from Euplotes crassus adds large numbers of TTTTGGGG repeats onto telomeric primers. Mol. Cell. Biol. 9 (6), 2761-2764 (1989).
30. Feng J, Funk WD, Wang S-S et al.: The RNA component of human telomerase. Science 269, 1236-1241 (1995).
31. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR: Protein composition of catalytically active human telomerase from immortal cells. Science 315 (5820), 1850-1853 (2007).
32. Mitchell JR, Wood E, Collins K: A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402 (6761), 551-555 (1999).
33. Greider CW, Blackburn EH: A telomeric sequence in the RNA of tetrahymena telomerase required for telomere repeat synthesis. Nature 337, 331-337. (1989).
34. Nakayama J, Tahara H, Tahara E et al.: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat. Genet. 18 (1), 65-68 (1998).
35. Collins K: Physiological assembly and activity of human telomerase complexes. Mech. Ageing Dev. 129 (1-2), 91-98 (2008).
36. Venteicher AS, Abreu EB, Meng Z et al.: A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 323 (5914), 644-648 (2009).
37. Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE: Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 132 (6), 945-957 (2008).
38. Stewart SA, Hahn WC, O'Connor BF et al.: Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl Acad. Sci. USA 99 (20), 12606-12611 (2002).
39. Oh H, Taffet GE, Youker KA et al.: Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc. Natl Acad. Sci. USA 98 (18), 10308-10313 (2001).
40. Shin KH, Kang MK, Dicterow E, Kameta A, Baluda MA, Park NH: Introduction of human telomerase reverse transcriptase to normal human fibroblasts enhances DNA repair capacity. Clin. Cancer Res. 10 (7), 2551-2560 (2004).
41. Cao Y, Li H, Deb S, Liu JP: TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 21 (20), 3130-3138 (2002).
42. Masutomi K, Possemato R, Wong JM et al.: The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl Acad. Sci. USA 102 (23), 8222-8227 (2005).
43. Smith LL, Coller HA, Roberts JM: Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat. Cell Biol. 5 (5), 474-479 (2003).
44. Flores I, Cayuela ML, Blasco MA: Effects of telomerase and telomere length on epidermal stem cell behavior. Science 309 (5738), 1253-1256 (2005). • Provides in vivo evidence of a noncanonical function of telomerase reverse transcriptase (TERT) by demonstrating that TERT overexpression in mouse skin promoted epithelial stem cell mobilization and proliferation without any apparent effect on telomere length.
45. Sarin KY, Cheung P, Gilison D et al.: Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436 (7053), 1048-1052 (2005). • Demonstrates that expression of TERT promotes proliferation of hair follicle stem cells through a mechanism that does not require telomerase RNA component (TERC) and therefore appears to be independent of the catalytic addition of telomere repeats.
46. Park JI, Venteicher AS, Hong JY et al.: Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460 (7251), 66-72 (2009). • Describes a direct molecular interaction of TERT and the chromatin remodeling protein BRG1 (SMARCA4) through the Wnt/p-catenin signaling pathway in murine epithelial progenitor cells and embryonic stem cells, which may explain some of the noncanonical functions observed when TERT is overexpressed.
47. Li S, Ferguson MJ, Hawkins CJ, Smith C, Elwood NJ: Human telomerase reverse transcriptase protects hematopoietic progenitor TF-1 cells from death and quiescence induced by cytokine withdrawal. Leukemia 20 (7), 1270-1278 (2006).
48. Imamura S, Uchiyama J, Koshimizu E et al.: A noncanonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis. PLoS One 3 (10), e3364 (2008). •• Demonstrates that TERT knockdown in zebra fish embryos causes apoptosis and pancytopenia, via a mechanism that is independent of telomere maintenance.
49. Liu Y, Kha H, Ungrin M, Robinson MO, Harrington L: Preferential maintenance of critically short telomeres in mammalian cells heterozygous for mTERT. Proc. Natl Acad. Sci. USA 99 (6), 3597-3602 (2002).
50. Ouellette MM, Liao M, Herbert BS et al.: Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J. Biol. Chem. 275 (14), 10072-10076 (2000).
51. Vidal-Cardenas SL, Greider CW: Comparing effects of mTR and mTERT deletion on gene expression and DNA damage response: a critical examination of telomere length maintenance-independent roles of telomerase. Nucleic Acids Res. 38 (1), 60-71 (2009).
52. Hiyama K, Hirai Y, Kyoizumi S et al.: Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155 (8), 3711-3715 (1995).
53. Chiu CP, Dragowska W, Kim NW et al.: Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 14 (2), 239-248 (1996).
54. Yui J, Chiu CP, Lansdorp PM: Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood 91 (9), 3255-3262 (1998).
55. Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MAS: Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 90, 182-193 (1997).
56. Gammaitoni L, Weisel KC, Gunetti M et al.: Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood 103 (12), 4440-4448 (2004).
57. Jaras M, Edqvist A, Rebetz J, Salford LG, Widegren B, Fan X: Human short-term repopulating cells have enhanced telomerase reverse transcriptase expression. Blood 108 (3), 1084-1091 (2006).
58. + progenitors predicts erythroid proliferative potential. Leukemia 21 (5), 983-991 (2007). • Study demonstrates that the telomere length of cord blood progenitor cells is predictive of their capacity for production of erythroid precursor cells in vitro.
59. Sharma HW, Sokoloski JA, Perez JR et al.: Differentiation of immortal cells inhibits telomerase activity. Proc. Natl Acad. Sci. USA 92 (26), 12343-12346 (1995).
60. Liu L, Saldanha SN, Pate MS, Andrews LG, Tollefsbol TO: Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation. Genes Chromosomes Cancer 41 (1), 26-37 (2004).
61. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J: Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int. J. Cancer 101 (4), 335-341 (2002).
62. Takakura M, Kyo S, Sowa Y et al.: Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res. 29 (14), 3006-3011 (2001).
63. Lai SR, Phipps SM, Liu L, Andrews LG, Tollefsbol TO: Epigenetic control of telomerase and modes of telomere maintenance in aging and abnormal systems. Front. Biosci. 10, 1779-1796 (2005).
64. Xu D, Gruber A, Bjorkholm M, Peterson C, Pisa P: Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms. Br. J. Cancer 80 (8), 1156-1161 (1999).
65. Meyerson M, Counter CM, Eaton EN et al.: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90 (4), 785-795 (1997).
66. Nakamura TM, Morin GB, Chapman KB et al.: Telomerase catalytic subunit homologs from fssion yeast and human. Science 277 (5328), 955-959 (1997).
67. Weinrich SL, Pruzan R, Ma L et al.: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Genet. 17 (4), 498-502 (1997).
68. Liu Y, Snow BE, Hande MP et al.: The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr. Biol. 10 (22), 1459-1462 (2000).
69. Beattie TL, Zhou W, Robinson MO, Harrington L: Reconstitution of human telomerase activity in vitro. Curr. Biol. 8 (3), 177-180 (1998).
70. Vaziri H, Benchimol S: Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8 (5), 279-282 (1998).
71. Wang JC, Warner JK, Erdmann N, Lansdorp PM, Harrington L, Dick JE: Dissociation of telomerase activity and telomere length maintenance in primitive human hematopoietic cells. Proc. Natl Acad. Sci. USA 102 (40), 14398-14403 (2005).
72. Zimmermann S, Glaser S, Ketteler R, Waller CF, Klingmuller U, Martens UM: Effects of telomerase modulation in human hematopoietic progenitor cells. Stem Cells 22 (5), 741-749 (2004).
73. Akimov SS, Ramezani A, Hawley TS, Hawley RG: Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells. Stem Cells 23 (9), 1423-1433 (2005).
74. Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL: Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 102 (2), 517-520 (2003).
75. Chen QM, Prowse KR, Tu VC, Purdom S, Linskens MH: Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts. Exp. Cell Res. 265 (2), 294-303 (2001).
76. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA: Telomerase activity and telomere length in acute and chronic Leukemia pre- and post-ex vivo culture. Cancer Res. 60 (3), 610-617 (2000).
77. 7. Frenck RW Jr, Blackburn EH, Shannon KM: The rate of telomere sequence loss in human leukocytes varies with age. Proc. Natl Acad. Sci. USA 95 (10), 5607-5610 (1998).
78. Iwama H, Ohyashiki K, Ohyashiki JH et al.: Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum. Genet. 102 (4), 397-402 (1998).
79. Rufer N, Brummendorf TH, Kolvraa S et al.: Telomere fuorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med. 190 (2), 157-167 (1999).
80. Rogan EM, Bryan TM, Hukku B et al.: Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol. Cell. Biol. 15 (9), 4745-4753 (1995).
81. Chang E, Harley CB: Telomere length and replicative aging in human vascular tissues. Proc. Natl Acad. Sci. USA 92 (24), 11190-11194 (1995).
82. Allsopp RC, Harley CB: Evidence for a critical telomere length in senescent human fibroblasts. Exp. Cell Res. 219 (1), 130-136 (1995).
83. Hayfick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585-621 (1961).
84. Smith J, Pereira-Smith OM: Replicative senescence: implications for in vivo aging and tumor suppression. Science 273, 63-66 (1996).
85. Dimri GP, Lee X, Basile G et al.: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92 (20), 9363-9367 (1995).
86. Johnson LK, Longenecker JP: Senescence of aortic endothelial cells in vitro: influence of culture conditions and preliminary characterization of the senescent phenotype. Mech. Ageing Dev. 18 (1), 1-18 (1982).
87. Johnson TE, Umbenhauer DR, Hill R et al.: Karyotypic and phenotypic changes during in vitro aging of human endothelial cells. J. Cell Physiol. 150 (1), 17-27 (1992).
88. Lansdorp PM, Dragowska W, Mayani H: Ontogeny-related changes in proliferative potential of human hematopoietic cells. J. Exp. Med. 178 (3), 787-791 (1993).
89. Chen J, Astle CM, Harrison DE: Genetic regulation of primitive hematopoietic stem cell senescence. Exp. Hematol. 28, 442-450 (2000).
90. Chen J, Astle CM, Harrison DE: Developement and aging of primitive hematopoietic stem cells in BALB/cBy mice. Exp. Hematol. 27, 928-935 (1999).
91. Harrison DE, Astle CM, Delaittre JA: Loss of proliferative capacity in immunohemopoietic stem cells caused by serial transplantation rather than aging. J. Exp. Med. 147 (5), 1526-1531 (1978).
92. Harrison DE: Long-term erythropoietic repopulating ability of old, young, and fetal stem cells. J. Exp. Med. 157 (5), 1496-1504 (1983).
93. Harrison DE, Astle CM: Loss of stem cell repopulating ability upon transplantation. Effects of donor age, cell number, and transplantation procedure. J. Exp. Med. 156 (6), 1767-1779 (1982).
94. Spencer A, Szydlo RM, Brookes PA et al.: Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 86 (9), 3590-3597 (1995).
95. Groves FD, Linet MS, Devesa SS: Patterns of occurrence of the leukaemias. Eur. J. Cancer 31 A (6), 941-949 (1995).
96. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG: Establishing the incidence of myelodysplastic syndrome. Br. J. Haematol. 87 (4), 743-745 (1994).
97. Allsopp RC, Cheshier S, Weissman IL: Telomere shortening accompanies increased cell cycle activity during serial transplantation of hematopoietic stem cells. J. Exp. Med. 193 (8), 917-924 (2001).
98. Lee HW, Blasco MA, Gottlieb GJ, Horner JW 2nd, Greider CW, DePinho RA: Essential role of mouse telomerase in highly proliferative organs. Nature 392 (6676), 569-574 (1998).
99. Samper E, Fernandez P, Eguia R et al.: Long-term repopulating ability of telomerasedefcient murine hematopoietic stem cells. Blood 99 (8), 2767-2775 (2002).
100. Marley SB, Lewis JL, Davidson RJ et al.: Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children. Br. J. Haematol. 106 (1), 162-166 (1999).
101. Van Ziffe JA, Baerlocher GM, Lansdorp PM: Telomere length in subpopulations of human hematopoietic cells. Stem Cells 21 (6), 654-660 (2003).
102. Ohyashiki JH, Ohyashiki K, Fujimura T et al.: Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res. 54 (13), 3557-3560 (1994).
103. Brummendorf TH, Macieejewski JP, Mak J, Young NS, Landsdorp PM: Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 97 (4), 895-900 (2001).
104. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC: Progressive telomere shortening in aplastic anemia. Blood 91 (10), 3582-3592 (1998).
105. Leteurtre F, Li X, Guardiola P et al.: Accelerated telomere shortening and telomerase activation in Fanconi's anemia. Br. J. Haematol. 105, 883-893 (1999).
106. Thornley I, Dror Y, Sung L, Wynn RF, Freedman MH: Abnormal telomere shortening in leucocytes of children with Shwachman-Diamond syndrome. Br. J. Haematol. 117 (1), 189-192 (2002).
107. Baerlocher GM, Sloand EM, Young NS, Lansdorp PM: Telomere length in paroxysmal nocturnal hemoglobinuria correlates with clone size. Exp. Hematol. 35 (12), 1777-1781 (2007).
108. Beier F, Balabanov S, Buckley T et al.: Accelerated telomere shortening in glycosylphosphatidylinositol (GPI) -negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin fow-FISH. Blood 106 (2), 531-533 (2005).
109. + hematopoiesis. Blood 102 (2), 514-516 (2003).
110. Du HY, Pumbo E, Ivanovich J et al.: TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 113 (2), 309-316 (2009). •• Study of 160 patients with a spectrum of bone marrow failure syndromes that revealed that patients with mutations in TERT or TERC invariably had telomere lengths in the first percentile of age-matched healthy controls.
111. Vulliamy T, Marrone A, Goldman F et al.: The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413 (6854), 432-435 (2001).
112. Alter BP, Baerlocher GM, Savage SA et al.: Very short telomere length by flow fuorescence in situ hybridization identifes patients with dyskeratosis congenita. Blood 110 (5), 1439-1447 (2007).
113. Dokal I: Dyskeratosis congenita in all its forms. Br. J. Haematol. 110 (4), 768-779 (2000).
114. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I: Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 107 (7), 2680-2685 (2006).
115. Calado RT, Young NS: Telomere diseases. N. Engl. J. Med. 361 (24), 2353-2365 (2009).
116. Heiss NS, Knight SW, Vulliamy TJ et al.: X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19 (1), 32-38 (1998).
117. Vulliamy TJ, Walne A, Baskaradas A, Mason PJ, Marrone A, Dokal I: Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol. Dis. 34 (3), 257-263 (2005).
118. Walne AJ, Vulliamy T, Marrone A et al.: Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP 10. Hum. Mol. Genet. 16 (13), 1619-1629 (2007).
119. Vulliamy TJ, Dokal I: Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex. Biochimie 90 (1), 122-130 (2008).
120. Wong JM, Collins K: Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev. 20 (20), 2848-2858 (2006).
121. Goldman FD, Aubert G, Klingelhutz AJ et al.: Characterization of primitive hematopoietic cells firom patients with dyskeratosis congenita. Blood 111 (9), 4523-4531 (2008).
122. Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I: TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 112 (9), 3594-3600 (2008).
123. Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP: TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am. J. Hum. Genet. 82 (2), 501-509 (2008).
124. Keith WN, Vulliamy T, Zhao J et al.: A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with paroxysmal nocturnal haemoglobinuria. BMC Blood Disord. 4 (1), 3 (2004).
125. Yamaguchi H, Calado RT, Ly H et al.: Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N. Engl. J. Med. 352 (14), 1413-1424 (2005). •• Demonstrates haploinsufficiency for telomerase activity in association with TERT mutations in patients with aplastic anemia.
126. Fogarty PF, Yamaguchi H, Wiestner A et al.: Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 362 (9396), 1628-1630 (2003).
127. Yamaguchi T, Takahashi H, Jinmei H, Takayama Y, Saneyoshi M: Inhibition of vertebrate telomerases by the triphosphate derivatives of some biologically active nucleosides. Nucleosides Nucleotides Nucleic Acids 22 (5-8), 1575-1577 (2003).
128. Degan P, Bonassi S, De Caterina M et al.: In vivo accumulation of 8-hydroxy-2'- deoxyguanosine in DNA correlates with release of reactive oxygen species in Fanconi's anaemia families. Carcinogenesis 16 (4), 735-741 (1995).
129. Wynn RF, Cross MA, Hatton C et al.: Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 351 (9097), 178-181 (1998).
130. Engelhardt M, Ozkaynak MF, Drullinsky P et al.: Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 12, 13-24 (1998).
131. Notaro R, Cimmino A, Tabarini D, Rotoli B, Luzzatto L: In vivo telomere dynamics of human hematopoietic stem cells. Proc. Natl Acad. Sci. USA 94 (25), 13782-13785 (1997).
132. Rufer N, Brummendorf TH, Chapuis B, Helg C, Lansdorp PM, Roosnek E: Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood 97 (2), 575-577 (2001).
133. Mathioudakis G, Storb R, McSweeney PA et al.: Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients. Blood 96 (12), 3991-3994. (2000).
134. Ohyashiki JH, Iwama H, Yahata N et al.: Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin. Cancer Res. 5 (5), 1155-1160 (1999).
135. Artandi SE, Chang S, Lee SL et al.: Telomere dysfunction promotes nonreciprocal translocations and epithelial cancers in mice. Nature 406 (6796), 641-645 (2000).
136. Chin L, Artandi SE, Shen Q et al.: p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97 (4), 527-538 (1999).
137. Adamson DJ, King DJ, Haites NE: Significant telomere shortening in childhood leukemia. Cancer Genet. Cytogenet. 61 (2), 204-206 (1992).
138. Yamada O, Oshimi K, Motoji T, Mizoguchi H: Telomeric DNA in normal and leukemic blood cells. J. Clin. Invest. 95 (3), 1117-1123 (1995).
139. Iwama H, Ohyashiki K, Ohyashiki JH et al.: The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia. Cancer 79 (8), 1552-1560 (1997).
140. Brummendorf TH, Holyoake TL, Rufer N et al.: Prognostic implications of differences in telomere length between normal and malignant cells firom patients with chronic myeloid leukemia measured by flow cytometry. Blood 95 (6), 1883-1890 (2000).
141. Boultwood J, Peniket A, Watkins F et al.: Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 96 (1), 358-361 (2000).
142. Damle RN, Batliwalla FM, Ghiotto F et al.: Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defned by immunoglobulin V gene mutations. Blood 103 (2), 375-382 (2004).
143. Broccoli D, Young JW, de Lange T: Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl Acad. Sci. USA 92 (20), 9082-9086 (1995).
144. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S: Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85 (9), 2315-2320 (1995).
145. Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW: Clinical implications of telomerase activity levels in acute leukemia. Clin. Cancer Res. 3 (4), 619-625 (1997).
146. Xu D, Gruber A, Peterson C, Pisa P: Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. Br. J. Haematol. 102 (5), 1367-1375 (1998).
147. Wu KD, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B, Moore MA: Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 101 (12), 4982-4989 (2003).
148. Norrback KF, Dahlenborg K, Carlsson R, Roos G: Telomerase activation in normal B lymphocytes and nonHodgkin's lymphomas. Blood 88 (1), 222-229 (1996).
149. Trentin L, Ballon G, Ometto L et al.: Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br. J. Haematol. 106 (3), 662-668 (1999).
150. Hartmann U, Brummendorf TH, Balabanov S, Thiede C, Illme T, Schaich M: Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 90 (3), 307-316 (2005).
151. Swiggers SJ, Kuijpers MA, de Cort MJ, Beverloo HB, Zijlmans JM: Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes Chromosomes Cancer 45 (3), 247-256 (2006).
152. Ohyashiki K, Ohyashiki JH, Fujimura T et al.: Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability. Cancer Genet. Cytogenet. 78 (1), 64-67 (1994).
153. Soder AI, Hoare SF, Muir S, Going JJ, Parkinson EK, Keith WN: Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 14 (9), 1013-1021 (1997).
154. Zhang L, Aviv H, Gardner JP et al.: Loss of chromosome 13 in cultured human vascular endothelial cells. Exp. Cell Res. 260 (2), 357-364 (2000).
155. Fan X, Wang Y, Kratz J et al.: hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am. J. Pathol. 162 (6), 1763-1769 (2003).
156. Nowak T, Januszkiewicz D, Zawada M et al.: Amplification of hTERT and hTERC genes in leukemic cells with high expression and activity of telomerase. Oncol. Rep. 16 (2), 301-305 (2006).
157. Guilleret I, Yan P, Guillou L, Braunschweig R, Coindre JM, Benhattar J: The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation. Carcinogenesis 23 (12), 2025-2030 (2002).
158. Strahl C, Blackburn EH: The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res. 22 (6), 893-900 (1994).
159. Strahl C, Blackburn EH: Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16 (1), 53-65 (1996).
160. Beltz L, Moran R, Elsawy O, Sadler J, Jurgenson J: The effects of telomerase inhibitors on lymphocyte function. Anticancer Res. 19 (4 B), 3205-3211 (1999).
161. Datta A, Bellon M, Sinha-Datta U et al.: Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108 (3), 1021-1029 (2006).
162. Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A: A prospective Phase II clinical trial with the use of zidovudine and interferon-α in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol. J. 3 (6), 276-282 (2002).
163. Hermine O, Bouscary D, Gessain A et al.: Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon α. N. Engl. J. Med. 332 (26), 1749-1751 (1995).
164. Zhang X, Mar. V, Zhou W, Harrington L, Robinson MO: Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 13 (18), 2388-2399 (1999).
165. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumor cells with defined genetic elements. Nature 400 (6743), 464-468 (1999).
166. Tauchi T, Nakajima A, Sashida G et al.: Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin. Cancer Res. 8 (11), 3341-3347 (2002).
167. Delhommeau F, Thierry A, Feneux D et al.: Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant. Oncogene 21 (54), 8262-8271 (2002).
168. Nakajima A, Tauchi T, Sashida G et al.: Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 17 (3), 560-567 (2003). • Suppression of telomerase activity and consequential telomere shortening in myeloid cell lines induced by the G-quadruplex inhibitor, telomestatin.
169. Roth A, Vercauteren S, Sutherland HJ, Lansdorp PM: Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 17 (12), 2410-2417 (2003).
170. Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR: Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 14 (5), 615-619 (1996).
171. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK: Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16 (25), 3323-3330 (1998).
172. Kondo S, Tanaka Y, Kondo Y et al.: Antisense telomerase treatment:
173. Corey DR: Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 21 (4), 631-637 (2002).
174. Pitts AE, Corey DR: Inhibition of human telomerase by 2'-O-methyl-RNA. Proc. Natl Acad. Sci. USA 95 (20), 11549-11554 (1998).
175. Herbert B, Pitts AE, Baker SI et al.: Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl Acad. Sci. USA 96 (25), 14276-14281 (1999).
176. Herbert BS, Pongracz K, Shay JW, Gryaznov SM: Oligonucleotide N3'→P5' phosphoramidates as efficient telomerase inhibitors. Oncogene 21 (4), 638-642 (2002).
177. Asai A, Oshima Y, Yamamoto Y et al.: A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 63 (14), 3931-3939 (2003).
178. Wang ES, Wu K, Chin AC et al.: Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103 (1), 258-266 (2004). •• Demonstrates that the telomerase RNA template agonist, GRN163, suppressed telomerase activity and abrogated growth of myeloma tumor cells in NOD/SCID mice.
179. Akiyama M, Hideshima T, Shammas MA et al.: Effects of oligonucleotide N3'→P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63 (19), 6187-6194 (2003).
180. Djojosubroto MW, Chin AC, Go N et al.: Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42 (5), 1127-1136 (2005).
181. Herbert BS, Gellert GC, Hochreiter A et al.: Lipid modifcation of GRN163, an N3'→P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24 (33), 5262-5268 (2005).
182. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW: Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 96 (1), 73-81 (2006).
183. Hochreiter AE, Xiao H, Goldblatt EM et al.: Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin. Cancer Res. 12 (10), 3184-3192 (2006).
184. Dikmen ZG, Gellert GC, Jackson S et al.: In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 65 (17), 7866-7873 (2005).
185. Shammas MA, Koley H, Bertheau RC et al.: Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 22 (7), 1410-1418 (2008).
186. Jackson SR, Zhu CH, Paulson V et al.: Antiadhesive effects of GRN163L - an oligonucleotide N3'→P5' thio-phosphoramidate targeting telomerase. Cancer Res. 67 (3), 1121-1129 (2007).
187. Harley CB: Telomerase and cancer therapeutics. Nat. Rev. Cancer 8 (3), 167-179 (2008).
188. Kraemer K, Fuessel S, Schmidt U et al.: Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. 9 (10 Pt 1), 3794-3800 (2003).
189. Folini M, Brambilla C, Villa R et al.: Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur. J. Cancer 41 (4), 624-634 (2005).
190. Yuan Z, Mei HD: Inhibition of telomerase activity with hTERT antisense increases the effect of CDDP-induced apoptosis in myeloid leukemia. Hematol. J. 3 (4), 201-205 (2002).
191. Zaffaroni N, Pennati M, Folini M: Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs. Methods Mol. Biol. 361, 239-263 (2007).
192. Kanazawa Y, Ohkawa K, Ueda K et al.: Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 225 (2), 570-576 (1996).
193. Wan MS, Fell PL, Akhtar S: Synthetic 2'-O-methyl-modifed hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev. 8 (4), 309-317 (1998).
194. Yokoyama Y, Takahashi Y, Shinohara A et al.: Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. 58 (23), 5406-5410 (1998).
195. Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaffaroni N: Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J. Invest. Dermatol. 114 (2), 259-267 (2000).
196. Yokoyama Y, Takahashi Y, Shinohara A et al.: The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem. Biophys. Res. Commun. 273 (1), 316-321 (2000).
197. Ludwig A, Saretzki G, Holm PS et al.: Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. 61 (7), 3053-3061 (2001).
198. Saretzki G, Ludwig A, von Zglinicki T, Runnebaum IB: Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 8 (10), 827-834 (2001).
199. Masutomi K, Yu EY, Khurts S et al.: Telomerase maintains telomere structure in normal human cells. Cell 114, 241-253 (2003).
200. Kosciolek BA, Kalantidis K, Tabler M, Rowley PT: Inhibition of telomerase activity in human cancer cells by RNA interference. Mol. Cancer Ther. 2 (3), 209-216 (2003).
201. Pallini R, Sorrentino A, Pierconti F et al.: Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. Int. J. Cancer 118 (9), 2158-2167 (2006).
202. Shammas MA, Koley H, Batchu RB et al.: Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol. Cancer 4, 24 (2005).
203. Yuan J, Yang BM, Zhong ZH et al.: Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase. Oncogene 28 (29), 2678-2689 (2009). • Reports that the expression of the chromosomal passenger protein, survivin, was downregulated following suppression of TERT but not TERC in tumor cells, suggesting that the therapeutic targeting of TERT may have additional effects to the targeting of TERC.
204. Li S, Rosenberg JE, Donjacour AA et al.: Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res. 64 (14), 4833-4840 (2004).
205. Gandellini P, Folini M, Bandiera R et al.: Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem. Pharmacol. 73 (11), 1703-1714 (2007).
206. Naasani I, Seimiya H, Yamori T, Tsuruo T: FJ5002: a potent telomerase inhibitor identifed by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 59 (16), 4004-4011 (1999).
207. Hayakawa N, Nozawa K, Ogawa A et al.: Isothiazolone derivatives selectively inhibit telomerase firom human and rat cancer cells in vitro. Biochemistry 38 (35), 11501-11507 (1999).
208. Damm K, Hemmann U, Garin-Chesa P et al.: A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 20 (24), 6958-6968 (2001).
209. Kleideiter E, Piotrowska K, Klotz U: Screening of telomerase inhibitors. Methods Mol. Biol. 405, 167-180 (2007).
210. Pascolo E, Wenz C, Lingner J et al.: Mechanism of human telomerase inhibition by BIBR1532, a synthetic, nonnucleosidic drug candidate. J. Biol. Chem. 277 (18), 15566-15572 (2002).
211. El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM: Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 105 (4), 1742-1749 (2005). •• The telomerase inhibitor BIBR1532 was demonstrated to be selectively toxic towards malignant hematopoietic cells at high concentrations and had no apparent effect on the clonogenicity of normal progenitors.
212. Zahler AM, Williamson JR, Cech TR, Prescott DM: Inhibition of telomerase by G-quartet DNA structures. Nature 350 (6320), 718-720 (1991).
213. Tang J, Kan ZY, Yao Y, Wang Q, Hao YH, Tan Z: G-quadruplex preferentially forms at the very 3' end of vertebrate telomeric DNA. Nucleic Acids Res. 36 (4), 1200-1208 (2008).
214. Mergny JL, Lacroix L, Teulade-Fichou MP et al.: Telomerase inhibitors based on quadruplex ligands selected by a fuorescence assay. Proc. Natl Acad. Sci. USA 98 (6), 3062-3067 (2001).
215. Izbicka E, Nishioka D, Marcell V et al.: Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. Anticancer Drug Des. 14 (4), 355-365 (1999).
216. Gowan SM, Harrison JR, Patterson L et al.: A G-quadruplex-interactive potent smallmolecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol. Pharmacol. 61 (5), 1154-1162 (2002).
217. Shin-ya K, Wierzba K, Matsuo K et al.: Telomestatin, a novel telomerase inhibitor firom Streptomyces anulatus. J. Am. Chem. Soc. 123 (6), 1262-1263 (2001).
218. Gowan SM, Heald R, Stevens MF, Kelland LR: Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol. Pharmacol. 60 (5), 981-988 (2001).
219. Cookson JC, Dai F, Smith V et al.: Pharmacodynamics of the G-quadruplexstabilizing telomerase inhibitor 3, 11-difluoro- 6, 8, 13-trimethyl-8H-quino[4, 3, 2-kl] acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol. Pharmacol. 68 (6), 1551-1558 (2005).
220. Shammas MA, Shmookler Reis RJ, Li C et al.: Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin. Cancer Res. 10 (2), 770-776 (2004).
221. Kim MY, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley LH: Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J. Am. Chem. Soc. 124 (10), 2098-2099 (2002).
222. Kim MY, Gleason-Guzman M, Izbicka E, Nishioka D, Hurley LH: The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res. 63 (12), 3247-3256 (2003).
223. Tauchi T, Shin-Ya K, Sashida G et al.: Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 22 (34), 5338-5347 (2003).
224. Tauchi T, Shin-ya K, Sashida G et al.: Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 25 (42), 5719-5725 (2006).
225. Sumi M, Tauchi T, Sashida G et al.: A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Int. J. Oncol. 24 (6), 1481-1487 (2004).
226. Grand CL, Han H, Munoz RM et al.: The cationic porphyrin TMPyP4 downregulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol. Cancer Ther. 1 (8), 565-573 (2002).
227. + T lymphocytes in patients with cancer. Blood 107 (4), 1505-1512 (2006).
228. Gannage M, Abel M, Michallet AS et al.: Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol. 174 (12), 8210-8218 (2005).
229. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 (6), 673-679 (1999).
230. Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21 (4), 674-679 (2002).
231. Nair SK, Heiser A, Boczkowski D et al.: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 6 (9), 1011-1017 (2000).
232. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S: Identification of human telomerase reverse transcriptasederived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97 (9), 2903-2907 (2001).
233. Cortez-Gonzalez X, Zanetti M: Telomerase immunity from bench to bedside: round one. J. Transl. Med. 5, 12 (2007).
234. Danet-Desnoyers GA, Luongo JL, Bonnet DA, Domchek SM, Vonderheide RH: Telomerase vaccination has no detectable effect on SCID-repopulating and colonyforming activities in the bone marrow of cancer patients. Exp. Hematol. 33 (11), 1275-1280 (2005).
235. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 3 (11), 1271-1274 (1997).
236. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR: Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 14 (17), 4240-4248 (1995).
237. Bechter OE, Zou Y, Walker W, Wright WE, Shay JW: Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res. 64 (10), 3444-3451 (2004).
238. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K: Telomeres and telomerase in hematologic neoplasia. Oncogene 21 (4), 680-687 (2002).